Given the above research background, this study reviews the application of the PI3K/PTEN/AKT signaling pathway in renal cell carcinoma, aiming to provide more references for the treatment of clinical renal cell carcinoma. This evidence concerns the gene AKT1 and hereditary clear cell renal cell carcinoma.